Overview Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS) Status: Enrolling by invitation Trial end date: 2022-08-15 Target enrollment: Participant gender: Summary This will be a 6-month, widely inclusive, virtual, single-center, open-label pilot trial utilizing a historical control group. Phase: Phase 2 Details Lead Sponsor: Richard Bedlack, M.D., Ph.D.